Irvin M. Modlin
Yale University
Internal medicineEndocrinologySurgeryPathologyOncologyMolecular biologyChemistryEnterochromaffin-like cellSomatostatinGastrinNeuroendocrine tumorsDiseaseRadionuclide therapySecretionCancer researchMedicineBiomarker (medicine)Chromogranin ABiologyEnterochromaffin cellGastroenterology
498Publications
81H-index
19.3kCitations
Publications 509
Newest
#1Lisa Bodei (IEO: European Institute of Oncology)H-Index: 50
#2Mark Kidd (Yale University)H-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 11 authors...
Purpose Peptide receptor radionuclide therapy (PRRT) with 90Y and 177Lu provides objective responses in neuroendocrine tumours, and is well tolerated with moderate toxicity. We aimed to identify clinical parameters predictive of long-term renal and haematological toxicity (myelodysplastic syndrome and acute leukaemia).
218 CitationsSource
#1Irvin M. ModlinH-Index: 81
#2Harry R. AslanianH-Index: 28
Last. Mark KiddH-Index: 66
view all 5 authors...
A critical requirement in neuroendocrine tumor (NET) management is a blood biomarker test that is sensitive, specific and reproducible. We evaluated a PCR-based 51-transcript signature to detect tumors, compared it with chromogranin A (CgA) and examined the confounding effect of proton pump inhibitors (PPIs), which cause falsely elevated CgA levels. The multigene signature was evaluated in two groups. Group 1: 125 prospectively collected NETs: gastroenteropancreatic NETs (nZ91, including 42 panc...
33 CitationsSource
#1Lisa Bodei (IEO: European Institute of Oncology)H-Index: 2
#2Mark Kidd (Yale University)H-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 4 authors...
: Peptide receptor radionuclide therapy is a treatment for inoperable or metastatic neuroendocrine tumors. A key issue is the need to standardize the treatment and develop randomized controlled trials. Standardization would help define the characteristics of response, including progression-free survival; provide homogeneous phase II and III studies; delineate the position of peptide receptor radionuclide therapy in the therapeutic algorithm for neuroendocrine tumors; and establish the basis for ...
15 CitationsSource
#1Lisa Bodei (IEO: European Institute of Oncology)H-Index: 50
#2Anders Sundin (Uppsala University)H-Index: 51
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 5 authors...
Diagnostic imaging plays a pivotal role in the diagnosis, staging, treatment selection and follow-up for neuroendocrine tumors. The available diagnostic strategies are morphologic imaging, including computed tomography, magnetic resonance imaging (MRI) and ultrasound techniques, and molecular imaging, including scintigraphy with 111In-pentetreotide and positron emission tomography with 68Ga-DOTA-peptides, 18F-DOPA and 11C-5-HTP. A combination of anatomic and functional techniques is routinely pe...
64 CitationsSource
#1Irvin M. ModlinH-Index: 81
#2Ignat DrozdovH-Index: 37
Last. Mark Kidd (Yale University)H-Index: 66
view all 4 authors...
Background Detection of neuroendocrine tumor (NET) disease progression is a key issue in determining management. Currently, assessment is by imaging (MRI/CT and Octreoscan®) and plasma Chromogranin A (CgA) measurement.
12 CitationsSource
#1Lisa Bodei (IEO: European Institute of Oncology)H-Index: 50
#2Marta Cremonesi (IEO: European Institute of Oncology)H-Index: 42
Last. Giovanni Paganelli (IEO: European Institute of Oncology)H-Index: 78
view all 7 authors...
: Peptide receptor radionuclide therapy (PRRT) consists of the systemic administration of a synthetic peptide, labeled with a suitable β-emitting radionuclide, able to irradiate tumors and their metastases via internalization through a specific receptor (usually somatostatin S2), over-expressed on the cell membrane. After almost 2 decades of experience, PRRT, with either (90)Y-octreotide or (177)Lu-octreotate, has established itself to be an efficient and effective therapeutic modality. As a tre...
38 CitationsSource
#1Irvin M. ModlinH-Index: 81
#2Ignat DrozdovH-Index: 37
Last. Mark KiddH-Index: 66
view all 7 authors...
: A critical requirement in neuroendocrine tumor (NET) management is a sensitive, specific and reproducible blood biomarker test. We evaluated a PCR-based 51 transcript signature (NETest) and compared it to chromogranin A (CgA), pancreastatin (PST) and neurokinin A (NKA). The multigene signature was evaluated in two groups: i) a validation set of 40 NETs and controls and ii) a prospectively collected group of NETs (n=41, 61% small intestinal, 50% metastatic, 44% currently treated and 41 age-sex ...
69 CitationsSource
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Lisa Bodei (IEO: European Institute of Oncology)H-Index: 50
Last. Mark Kidd (Yale University)H-Index: 66
view all 3 authors...
Abstract In the three-quarters of a century that have elapsed since the first description of a bronchial carcinoid, the field has progressed from serendipitous radiological or bronchoscopic diagnosis to computed tomography, magnetic resonance imaging, and somatostatin receptor imaging identification. Similarly, pathologic techniques have advanced from a naive assessment of neoplasia to a delineation of several tumor subtypes and an understanding of the neuroendocrine basis of the disease process...
4 CitationsSource
#1Lisa Bodei (IEO: European Institute of Oncology)H-Index: 50
#2Mark Kidd (Yale University)H-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 6 authors...
Early identification of neuroendocrine tumors (NETs) is a critical prerequisite to establishing effective treatment. While substantial advances have occurred in the last two decades, there is little progress regarding the identification of small subcentimeter lesions and the determination of tumor proliferative rates and metabolic characteristics. At this time, delineation of lesions mainly utilizes various combinations of somatostatin receptor (SSR) density, glucose metabolism and Hounsfield un...
7 CitationsSource
#1Simon Schimmack (Yale University)H-Index: 14
#2Andrew Taylor (Yale University)H-Index: 5
Last. Mark Kidd (Yale University)H-Index: 66
view all 8 authors...
Background The chromatin remodeler NAP1L1, which is upregulated in small intestinal neuroendocrine neoplasms (NENs), has been implicated in cell cycle progression. As p57Kip2 (CDKN1C), a negative regulator of proliferation and a tumor suppressor, is controlled by members of the NAP1 family, we tested the hypothesis that NAP1L1 may have a mechanistic role in regulating pancreatic NEN proliferation through regulation of p57Kip2.
32 CitationsSource